Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curdin Conrad

Showing results (21-30 of 117) with videos related to

Pageof 12
Sort By:
JAMA Dermatology|July 31, 2024
Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With PsoriasisAndrew Blauvelt, Curdin Conrad, Megan H Noe
Current Opinion in Immunology|March 16, 2005
Dendritic-cell-based therapeutic vaccination against cancerFrank O Nestle, Arpad Farkas, Curdin Conrad
Revue Medicale Suisse|April 2, 2024
[Treatment of childhood psoriasis: present and future]Francesco Messina, Curdin Conrad, Marie-Anne Morren
Journal of the European Academy of Dermatology and Venereology : JEADV|September 18, 2024
Single-centre experience with tralokinumab in dupilumab-experienced and naïve patients with atopic dermatitisClaire Fossati, Emmanuella Guenova, Curdin Conrad, et al.
Trends in Immunology|January 2, 2007
The pathogenic role of tissue-resident immune cells in psoriasisOnur Boyman, Curdin Conrad, Giulia Tonel, et al.
International Journal of Molecular Sciences|November 13, 2025
Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety ReviewSimone Lisa Böll, Seyed Morteza Seyed Jafari, Curdin Conrad, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 26, 2025
Dermatology 2.0: Precision medicine for inflammatory skin diseasesJeremy Di Domizio, Antoine Girardin, Curdin Conrad, et al.
Dermatology and Therapy|December 6, 2021
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe PsoriasisCurdin Conrad, Christine-Elke Ortmann, Marc Vandemeulebroecke, et al.
Dermatology (Basel, Switzerland)|November 7, 2013
Anti-TNF therapy in the treatment of psoriasis in a patient with acute-on-chronic pancreatitisHelena Clayton, Lukas Flatz, Sonia Vollenweider-Roten, et al.
The Journal of Dermatological Treatment|June 13, 2020
Ixekizumab and ustekinumab in psoriasis: <i>post-hoc</i> comparison of onset and duration of treatment responseMarc Radtke, Curdin Conrad, Christopher Schuster, et al.
Pageof 12

Showing results (21-30 of 117) with videos related to

Sort By:
Pageof 12
JAMA Dermatology|July 31, 2024
Extending Maintenance Dosing Intervals for Guselkumab in the Treatment of Patients With PsoriasisAndrew Blauvelt, Curdin Conrad, Megan H Noe
Current Opinion in Immunology|March 16, 2005
Dendritic-cell-based therapeutic vaccination against cancerFrank O Nestle, Arpad Farkas, Curdin Conrad
Revue Medicale Suisse|April 2, 2024
[Treatment of childhood psoriasis: present and future]Francesco Messina, Curdin Conrad, Marie-Anne Morren
Journal of the European Academy of Dermatology and Venereology : JEADV|September 18, 2024
Single-centre experience with tralokinumab in dupilumab-experienced and naïve patients with atopic dermatitisClaire Fossati, Emmanuella Guenova, Curdin Conrad, et al.
Trends in Immunology|January 2, 2007
The pathogenic role of tissue-resident immune cells in psoriasisOnur Boyman, Curdin Conrad, Giulia Tonel, et al.
International Journal of Molecular Sciences|November 13, 2025
Topical Ruxolitinib and Delgocitinib Versus Systemic JAK Inhibitors: A Comparative Safety ReviewSimone Lisa Böll, Seyed Morteza Seyed Jafari, Curdin Conrad, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 26, 2025
Dermatology 2.0: Precision medicine for inflammatory skin diseasesJeremy Di Domizio, Antoine Girardin, Curdin Conrad, et al.
Dermatology and Therapy|December 6, 2021
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe PsoriasisCurdin Conrad, Christine-Elke Ortmann, Marc Vandemeulebroecke, et al.
Dermatology (Basel, Switzerland)|November 7, 2013
Anti-TNF therapy in the treatment of psoriasis in a patient with acute-on-chronic pancreatitisHelena Clayton, Lukas Flatz, Sonia Vollenweider-Roten, et al.
The Journal of Dermatological Treatment|June 13, 2020
Ixekizumab and ustekinumab in psoriasis: <i>post-hoc</i> comparison of onset and duration of treatment responseMarc Radtke, Curdin Conrad, Christopher Schuster, et al.
Pageof 12